iBio Inc（IBIO）のニュースとイベントIBIOiBio Inc

iBio Highlights IBIO-610 Study Data at EASD Meeting

iBio highlighted preclinical body-composition data from its obese non-human primate, or NHP, study evaluating IBIO-610, alone and in combination with semaglutide, a GLP-1 receptor agonist used to treat obesity. The data were discussed in an oral presentation at the European Association for the Study of Diabetes, or EASD, annual meeting on October 1. Additional analysis of the eight-week obese NHP study further characterized the potential for IBIO-610 to support muscle preservation when combined with semaglutide. At week 8, fat accounted for 93% of the weight lost by NHPs given a single dose of IBIO-610 alongside twice-weekly semaglutide, compared with 77% for NHPs given semaglutide alone. These results build on previously reported data from this NHP study, in which IBIO-610 demonstrated a 97% reduction in serum levels of active Activin E at week 8 following a single intravenous dose. The study also found that IBIO-610 had a 33.2-day half-life in NHPs, with a projected human half-life potentially supporting twice-yearly dosing.

iBio Appoints Molly Carr as Chief Medical Officer

iBio (IBIO) announced the appointment of Molly Carr as chief medical officer as the company advances its clinical-stage cardiometabolic pipeline. Most recently, she served as clinical head and associate VP of Lilly's (LLY) insulin and glucagon franchise.

iBio Announces New Preclinical Data for IBIO-610

iBio announced new preclinical data from its obese non-human primate, or NHP, study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate. Following a single dose of IBIO-610, active Activin E levels in the blood were reduced in all treated NHPs and remained suppressed through eight weeks. At both weeks 4 and 8, active Activin E levels were reduced to levels below the limits of the assay. Overall, active Activin E was reduced by 98% at week 4 and 97% at week 8 compared with baseline. These findings support IBIO-610's potential for best-in-class pathway inhibition and further support the potential for an infrequently dosed, long-acting antibody approach. The data also demonstrated IBIO-610's potential to promote fat-selective weight loss while preserving lean mass. In obese NHPs, when combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while reducing lean mass loss by 73% versus semaglutide alone, further supporting its potential as both a stand-alone therapy and a complementary approach to GLP-1-based treatments.